BioAge Labs (BIOA) EPS (Weighted Average and Diluted) (2023 - 2026)

BioAge Labs has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.52 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.52, down 44.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 (down 1946.15% YoY), and the FY2025 annual result was -$2.24, up 66.21% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.52 for Q1 2026 at BioAge Labs, up from -$0.72 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $15.13 in Q4 2024 to a low of -$12.53 in Q4 2023.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.72 (2025), against an average of -$2.85.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 220.75% in 2024 and tumbled 104.76% in 2025, its largest moves.
• BioAge Labs' EPS (Weighted Average and Diluted) stood at -$12.53 in 2023, then jumped by 220.75% to $15.13 in 2024, then sank by 104.76% to -$0.72 in 2025, then gained by 27.78% to -$0.52 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.52 (Q1 2026), -$0.72 (Q4 2025), and -$0.56 (Q3 2025), per Business Quant data.